🚀 VC round data is live in beta, check it out!
Xencor Valuation Multiples
Discover revenue and EBITDA valuation multiples for Xencor and similar public comparables like Bioage Labs, Hyundai Bioscience, Arvinas, Pacira BioSciences and more.
Xencor Overview
About Xencor
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Founded
1997
HQ
Employees
250
Website
Sectors
Financials (LTM)
EV
$477M
Xencor Financials
Xencor reported last 12-month revenue of $125M and negative EBITDA of ($155M).
In the same LTM period, Xencor generated $125M in gross profit, ($155M) in EBITDA losses, and had net loss of ($119M).
Revenue (LTM)
Xencor P&L
In the most recent fiscal year, Xencor reported revenue of $126M and EBITDA of ($47M).
Xencor expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $125M | XXX | $126M | XXX | XXX | XXX |
| Gross Profit | $125M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($155M) | XXX | ($47M) | XXX | XXX | XXX |
| EBITDA Margin | (125%) | XXX | (38%) | XXX | XXX | XXX |
| EBIT Margin | (152%) | XXX | (141%) | XXX | XXX | XXX |
| Net Profit | ($119M) | XXX | ($92M) | XXX | XXX | XXX |
| Net Margin | (95%) | XXX | (73%) | XXX | XXX | XXX |
| Net Debt | — | — | $66M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Xencor Stock Performance
Xencor has current market cap of $878M, and enterprise value of $477M.
Market Cap Evolution
Xencor's stock price is $12.30.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $477M | $878M | 0.0% | XXX | XXX | XXX | $-1.29 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialXencor Valuation Multiples
Xencor trades at 3.8x EV/Revenue multiple, and (3.1x) EV/EBITDA.
EV / Revenue (LTM)
Xencor Financial Valuation Multiples
As of March 21, 2026, Xencor has market cap of $878M and EV of $477M.
Equity research analysts estimate Xencor's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Xencor has a P/E ratio of (7.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $878M | XXX | $878M | XXX | XXX | XXX |
| EV (current) | $477M | XXX | $477M | XXX | XXX | XXX |
| EV/Revenue | 3.8x | XXX | 3.8x | XXX | XXX | XXX |
| EV/EBITDA | (3.1x) | XXX | (10.1x) | XXX | XXX | XXX |
| EV/EBIT | (2.5x) | XXX | (2.7x) | XXX | XXX | XXX |
| EV/Gross Profit | 3.8x | XXX | — | XXX | XXX | XXX |
| P/E | (7.4x) | XXX | (9.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (3.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Xencor Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Xencor Margins & Growth Rates
Xencor's revenue in the last 12 month grew by 3%.
Xencor's revenue per employee in the last FY averaged $0.5M.
Xencor's rule of 40 is (122%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Xencor's rule of X is (118%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Xencor Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | (4%) | XXX | XXX | XXX |
| EBITDA Margin | (125%) | XXX | (38%) | XXX | XXX | XXX |
| EBITDA Growth | (34%) | XXX | 139% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (122%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (118%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | — | XXX | XXX | XXX |
| G&A Expenses to Revenue | 52% | XXX | 51% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 198% | XXX | 191% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 241% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Xencor Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Bioage Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Hyundai Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Arvinas | XXX | XXX | XXX | XXX | XXX | XXX |
| Pacira BioSciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Xencor M&A Activity
Xencor acquired XXX companies to date.
Last acquisition by Xencor was on XXXXXXXX, XXXXX. Xencor acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Xencor
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialXencor Investment Activity
Xencor invested in XXX companies to date.
Xencor made its latest investment on XXXXXXXX, XXXXX. Xencor invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Xencor
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Xencor
| When was Xencor founded? | Xencor was founded in 1997. |
| Where is Xencor headquartered? | Xencor is headquartered in United States. |
| How many employees does Xencor have? | As of today, Xencor has over 250 employees. |
| Who is the CEO of Xencor? | Xencor's CEO is Bassil I. Dahiyat. |
| Is Xencor publicly listed? | Yes, Xencor is a public company listed on Nasdaq. |
| What is the stock symbol of Xencor? | Xencor trades under XNCR ticker. |
| When did Xencor go public? | Xencor went public in 2013. |
| Who are competitors of Xencor? | Xencor main competitors are Bioage Labs, Hyundai Bioscience, Arvinas, Pacira BioSciences. |
| What is the current market cap of Xencor? | Xencor's current market cap is $878M. |
| What is the current revenue of Xencor? | Xencor's last 12 months revenue is $125M. |
| What is the current revenue growth of Xencor? | Xencor revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Xencor? | Current revenue multiple of Xencor is 3.8x. |
| Is Xencor profitable? | No, Xencor is not profitable. |
| What is the current EBITDA of Xencor? | Xencor has negative EBITDA and is not profitable. |
| What is Xencor's EBITDA margin? | Xencor's last 12 months EBITDA margin is (125%). |
| What is the current EV/EBITDA multiple of Xencor? | Current EBITDA multiple of Xencor is (3.1x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.